We have to remember the market cap hit over $300m last year purely on the basis of CEO change, possibly with the thought of a more speedy, more definitive path forward. I think the technical path forward is clear, the commercial not so, but it does hinge on the technical outcomes.
in saying that the decision to go depression vs Fragile. X was a commercial one, that could be a bigger market than the aspects of AD we are targeting.
This stock could go anywhere, another rise to $300m or even an IMU market cap.
Its all speculative until we get big pharma interest.
We have to remember the market cap hit over $300m last year...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
